CN106604928A - 用于α‑螺旋拟态的大环肽模拟物 - Google Patents

用于α‑螺旋拟态的大环肽模拟物 Download PDF

Info

Publication number
CN106604928A
CN106604928A CN201580029301.XA CN201580029301A CN106604928A CN 106604928 A CN106604928 A CN 106604928A CN 201580029301 A CN201580029301 A CN 201580029301A CN 106604928 A CN106604928 A CN 106604928A
Authority
CN
China
Prior art keywords
group
amino acid
macrocyclic
peptidomimetic molecule
macrocyclic peptidomimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580029301.XA
Other languages
English (en)
Chinese (zh)
Inventor
鲁迪·法桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of CN106604928A publication Critical patent/CN106604928A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580029301.XA 2014-04-02 2015-04-01 用于α‑螺旋拟态的大环肽模拟物 Pending CN106604928A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973994P 2014-04-02 2014-04-02
US61/973,994 2014-04-02
PCT/US2015/023883 WO2015153761A2 (en) 2014-04-02 2015-04-01 Macrocyclic peptidomimetics for alpha-helix mimicry

Publications (1)

Publication Number Publication Date
CN106604928A true CN106604928A (zh) 2017-04-26

Family

ID=54241434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029301.XA Pending CN106604928A (zh) 2014-04-02 2015-04-01 用于α‑螺旋拟态的大环肽模拟物

Country Status (6)

Country Link
US (1) US10294273B2 (enExample)
EP (1) EP3126375B1 (enExample)
JP (1) JP6642887B2 (enExample)
CN (1) CN106604928A (enExample)
CA (1) CA2944651A1 (enExample)
WO (1) WO2015153761A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3748558A1 (en) 2016-06-13 2020-12-09 Google LLC Automated telephone call initiating system and method
US10827064B2 (en) 2016-06-13 2020-11-03 Google Llc Automated call requests with status updates
US11479581B2 (en) 2017-06-09 2022-10-25 Bristol-Myers Squibb Company Non-chromatographic purification of macrocyclic peptides by a resin catch and release
WO2018232062A1 (en) 2017-06-15 2018-12-20 University Of Washington Macrocyclic polypeptides
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
US11510991B2 (en) 2017-10-27 2022-11-29 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
US11468893B2 (en) 2019-05-06 2022-10-11 Google Llc Automated calling system
US11158321B2 (en) 2019-09-24 2021-10-26 Google Llc Automated calling system
JP7392128B2 (ja) 2020-03-20 2023-12-05 グーグル エルエルシー 人間の参加者の代理の自動アシスタントによる準委任通話
US11303749B1 (en) 2020-10-06 2022-04-12 Google Llc Automatic navigation of an interactive voice response (IVR) tree on behalf of human user(s)
US20250042961A1 (en) * 2021-12-10 2025-02-06 Merck Sharp & Dohme Llc P53 peptidomimetic macrocycles
TW202417465A (zh) 2022-08-23 2024-05-01 日商富士軟片股份有限公司 環肽或其鹽及ｍｄｍｘ抑制劑
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides
US12225158B2 (en) 2022-12-15 2025-02-11 Google Llc System(s) and method(s) for implementing a personalized chatbot
KR20250134670A (ko) 2023-01-16 2025-09-11 암브룩스, 인코포레이티드 항-cd70 항체-약물 접합체
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090388A1 (en) * 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US20140057857A1 (en) * 2010-12-15 2014-02-27 The Research Foundation For The State University Of New York Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
AU2007333846B2 (en) * 2006-12-14 2014-01-23 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
WO2009149339A2 (en) 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
CN102203126A (zh) * 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
EP2376100B1 (en) * 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) * 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
CA2807685C (en) * 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
WO2012100176A2 (en) * 2011-01-20 2012-07-26 University Of Rochester Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090388A1 (en) * 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US20140057857A1 (en) * 2010-12-15 2014-02-27 The Research Foundation For The State University Of New York Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JESSICA M. SMITH等: "Modular Assembly of Macrocyclic Organo–Peptide Hybrids Using Synthetic and Genetically Encoded Precursors", 《ANGEWANDTE CHEMIE》 *
JOHN R.等: "Macrocyclization of Organo-Peptide Hybrids through a Dual Bio-orthogonal Ligation: Insights from Structure-Reactivity Studies", 《CHEMBIOCHEM》 *
MARAGANI SATYANARAYANA等: "Diverse organo-peptide macrocycles via a fast and catalyst-free oxime/intein-mediated dual ligation", 《CHEMCOMM》 *

Also Published As

Publication number Publication date
EP3126375A2 (en) 2017-02-08
JP6642887B2 (ja) 2020-02-12
EP3126375B1 (en) 2023-12-13
JP2017513826A (ja) 2017-06-01
CA2944651A1 (en) 2015-10-08
WO2015153761A2 (en) 2015-10-08
US10294273B2 (en) 2019-05-21
EP3126375A4 (en) 2018-01-24
WO2015153761A3 (en) 2015-11-26
US20170037084A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
JP6642887B2 (ja) アルファヘリックスを模倣した大環状ペプチドミメティック
US20230119612A1 (en) Peptidomimetic macrocycles
JP6785932B2 (ja) 構築されたポリペプチド特異性のモジュレーション
JP6259861B2 (ja) ビス−スルフヒドリル大環状化系
US10300109B2 (en) Peptidomimetic macrocycles
CN112119085B (zh) 稳定肽-介导的靶向蛋白降解
US10227380B2 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
DK2118123T3 (en) Stabilized p53 peptides and uses thereof
US20120178700A1 (en) Peptidomimetic macrocycles
JP2018012703A (ja) 構造化ポリペプチドの特異性のモジュレーション
EP2331567A1 (en) Peptidomimetic macrocycles
JP2024501019A (ja) Ｓｏｓの架橋ヘリックス二量体模倣体およびそれを使用する方法
HK1137184B (en) Bis-sulfhydryl macrocyclization systems
AU2016210709A1 (en) Stabilized p53 peptides and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170426